Answers are grounded in this paper and cite their sources.
Low-grade uterine adenosarcoma is a rare neoplasm accounting for 5.5–9 % of all uterine sarcomas. First described by Clement and Scully in 1974, it is characterized by benign endometrial glands combined with a low-grade malignant mesenchymal stroma. We report the case of a 77-year-old woman without known risk factors (endometriosis, hormonal therapy, or pelvic radiotherapy) who presented with intermittent metrorrhagia. Pelvic ultrasound and clinical examination revealed a uterine mass, and diagnostic hysteroscopy with polypectomy confirmed low-grade adenosarcoma (5 mitoses per 10 high-power fields, moderate stromal invasion). Pelvic MRI demonstrated a well-circumscribed lesion measuring 54 × 68 × 100 mm without deep myometrial invasion or dissemination. The patient underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy; the surgical specimen confirmed FIGO stage IB disease with positive estrogen and progesterone receptors. Following an uneventful postoperative course and a negative chest CT, adjuvant therapy with anastrozole 1 mg daily was initiated, and follow-up was scheduled every three months clinically and every six months with pelvic imaging. This case underscores the importance of precise histopathological diagnosis, long-term surveillance, and the potential benefit of adjuvant hormone therapy in the absence of sarcomatous overgrowth.
No takes yet. Share an insight, caveat, or question.
Camejo et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: